Abstract

The T50 Test for Improved Coordination of Interventions in Chronic Kidney Disease (CKD) Patients

Vincent Linder, Founder and President, CDP BioMedical Consulting

Despite multiple drugs and diagnostics used today, most chronic kidney disease (CKD) patients still die of cardiovascular (CV) complications, and a prognosis for CKD patients is often as poor as that of some solid tumors.  Calciscon offers the T50 blood test to identify patients with elevated risk of CV complications.  Then, treating physicians use the T50 result to coordinate interventions, repeat the T50 to assess the efficacy of their intervention, and adjust treatment as needed until the T50 improves.  In this contribution we discuss the foundational work that led to the invention of the T50, and its clinical validation across multiple cohorts of CKD patients.